Fertility Test Market: Growth, Trends, and Key Insights

The global fertility test market was valued at USD 629.43 million in 2024 and is projected to grow from USD 680.42 million in 2025 to USD 1,268.77 million by 2033, registering a CAGR of 8.1% during the forecast period. Fertility testing is a medical and physical assessment to determine whether an individual can naturally conceive and carry a pregnancy to term. With aging being a factor affecting fertility, individuals over 35 who have been trying to conceive for six months without success are advised to undergo testing. The process generally begins with a medical history review, followed by minimally invasive blood tests, ovulation testing, and sperm analysis for men.
Market Growth Factors
Rise in Consumer Awareness: Awareness campaigns and annual events like National Infertility Awareness Week in the U.S. help educate people on the importance of fertility testing, driving demand. Organizations such as IVF Babble also provide resources and support for individuals facing fertility challenges.
Technological Advancements: Innovative products like Modern Fertility's pregnancy and ovulation kits, paired with dedicated apps, and FDA-approved at-home ovulation kits like Prov, are making fertility testing more accurate and convenient. Advanced apps like OvuSense V.2 improve cycle tracking, increasing market adoption.
Declining Fertility Rates: Global fertility rates have dropped by 50% over the past 70 years due to factors such as women's workforce participation, lower infant mortality, and rising child-rearing costs, driving the need for fertility testing solutions.
Market Restraints
PCOS and Ovulation Monitor Limitations: Women with polycystic ovary syndrome (PCOS) may experience consistently high luteinizing hormone or estrogen levels, leading to inaccurate ovulation test results, which can impede market growth.
Lack of Awareness: Many underdeveloped regions still lack knowledge about fertility tests, their usage, and benefits, posing a challenge for market expansion.
Accuracy Issues: Ovulation tests detect hormones leading to ovulation but cannot confirm it. Medication use, age above 40, and conditions like PCOS can affect test reliability.
Market Opportunities
Online Sales Growth: Fertility testing devices are increasingly available on e-commerce platforms like Amazon, Flipkart, Walmart, and company websites, improving accessibility and boosting market potential.
Lifestyle Changes: Rising per capita income and technological advancements allow people to test for ovulation and pregnancy at home, increasing market adoption.
Regional Insights
Asia-Pacific: The largest market contributor, growing at a CAGR of 8.7%, driven by high PCOS prevalence, demand for home-based testing, and awareness campaigns.
Europe: Second-largest contributor, expected to reach USD 305.09 million with a CAGR of 8.2%, supported by technological adoption and awareness initiatives by organizations like the Fertility Europe Association (FEA).
North America: Third-largest contributor, fueled by awareness campaigns, high-tech products, and the presence of major players like Church & Dwight Co., Abbott Laboratories, and Quidel Corporation.
LAMEA: Emerging market with potential due to growing target demographics, increased fertility test demand, and introduction of new products.
Product Insights
Ovulation Prediction Kits: The largest segment, growing at a CAGR of 7.9%, benefiting from technological innovations and proprietary platforms.
Fertility Monitors: Second-largest, expected to reach USD 331.70 million by 2030 with a CAGR of 8.8%, driven by awareness, first-time pregnancies, declining fertility rates, and advanced product launches.
Mode of Purchase Insights
OTC-Based Tests: The leading segment with a CAGR of 8.3%, driven by convenience and widespread availability.
Prescription-Based Tests: Second-largest, growing at a CAGR of 6.9%, offering precise ovulation verification for medical professionals.
Application Insights
Female Fertility Testing: The highest contributor, CAGR of 8.3%, influenced by PCOS prevalence, first-time pregnancies, and advanced product adoption.
Male Fertility Testing: Second-largest, expected CAGR of 7.4%, analyzing sperm count, shape, and motility to determine fertility.
End-User Insights
Home Care Settings: Leading segment, CAGR of 8.4%, offering convenience and continuous care support.
Hospitals/Fertility Clinics: Second-largest, CAGR of 7.5%, providing specialized treatments like ovulation induction and fertility medications.
Key Players
Church & Dwight Co. Inc., Fairhaven Health LLC, Fertility Focus Limited, Geratherm Medical AG, HiLin Life Products Inc., Prestige Brands Holdings Inc., Quidel Corporation, Abbott Laboratories, UEBE Medical, Advacare Pharma
Recent Developments
-
Sept 2022: Church & Dwight acquired Hero (Mighty Patch® Brand) for USD 630 million.
-
Dec 2022: Quidel TriageTrue® High-Sensitivity Troponin I Test licensed by Health Canada.
-
Dec 2022: QuidelOrtho and Runda Medical JV to produce VITROS® assays.
-
Feb 2023: Abbott received CE Mark for TactiFlex™ Ablation Catheter and FDA approval for FlexAbility™ Catheter indications.
About Us:
Straits Research is a leading global market intelligence and consulting firm, dedicated to delivering actionable insights and in-depth analysis across a wide range of industries. Our mission is to empower organizations, investors, and decision-makers with reliable data, strategic guidance, and forward-looking perspectives to help them thrive in a rapidly evolving business landscape.
Contact Us:
Email: sales@straitsresearch.com
Tel: +1 646 905 0080 (U.S.), +44 203 695 0070 (U.K.)
Website: https://straitsresearch.com/